Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Triple Negative Breast Neoplasms × sabizabulin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Metastatic Castration Resistant Prostate Cancer 1 Breast Neoplasms 1

Interventions

pembrolizumab 66 Carboplatin 39 Paclitaxel 37 130-nm albumin-bound paclitaxel 31 Gemcitabine 29 Nivolumab 19 Capecitabine 18 atezolizumab 17 Cyclophosphamide 17 Albumin-Bound Paclitaxel 16 spartalizumab 11 sacituzumab govitecan 11 Doxorubicin 9 eribulin 8 Bevacizumab 8 olaparib 7 durvalumab 7 Cisplatin 7 Fluorouracil 6 Docetaxel 6 fludarabine 5 budigalimab 5 avelumab 5 Vinorelbine 5 Leucovorin 5 Injections 5 Fulvestrant 5 toripalimab 4 lenvatinib 4 iniparib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05008510 2022-02-08

VERU-111

Veru Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡